Experienced in Chronic Cough

Dr. Bruce G. Rankin

Family Medicine
999 W Plymouth Ave, 
Deland, FL 
Accepting New Patients
Experienced in Chronic Cough
999 W Plymouth Ave, 
Deland, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bruce Rankin is a primary care provider, practicing in Family Medicine in Deland, Florida. Dr. Rankin is rated as an Experienced provider by MediFind in the treatment of Chronic Cough. His top areas of expertise are Sitosterolemia, Painful Menstrual Periods, High Cholesterol, and Glucocorticoid-Remediable Aldosteronism. Dr. Rankin is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 26 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

999 W Plymouth Ave, Deland, FL 32720

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain
An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Qutenza (Capsaicin) 8% Topical System, Capsaicin 0.04% Topical System
Study Phase: Phase 3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: LY3372993
Study Phase: Phase 1
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
Enrollment Status: Completed
Publish Date: March 04, 2025
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Multi-center, Prospective, Open-label, Controlled Study of the Pharmacokinetics and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injuries
A Multi-center, Prospective, Open-label, Controlled Study of the Pharmacokinetics and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injuries
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Drug
Study Drug: Pentosan Polysulfate Sodium
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drug: X0002
Study Phase: Phase 3
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: January 29, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers
A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers
Enrollment Status: Completed
Publish Date: April 12, 2023
Intervention Type: Drug
Study Phase: Phase 1
Multi-Center Study of a Point-of-Care Immunoassay for the Detection of Bacterial Sinusitis
Multi-Center Study of a Point-of-Care Immunoassay for the Detection of Bacterial Sinusitis
Enrollment Status: Terminated
Publish Date: April 12, 2023
Intervention Type: Diagnostic test
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: PSD502
Study Phase: Phase 2
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Enrollment Status: Completed
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
LY2951742 Biomarker Study in Patients With Migraine
LY2951742 Biomarker Study in Patients With Migraine
Enrollment Status: Completed
Publish Date: April 09, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 24 Less Clinical Trials

3 Total Publications

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Journal: Human vaccines & immunotherapeutics
Published: October 14, 2024
Similar Doctors
Distinguished in Chronic Cough
Dr. Shirley A. Ice
Family Medicine
Distinguished in Chronic Cough
Dr. Shirley A. Ice
Family Medicine
2500 Citrus Blvd, 
Leesburg, FL 
 (37.2 miles away)
352-726-8282
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shirley Ice is a primary care provider, practicing in Family Medicine in Leesburg, Florida. Dr. Ice is rated as a Distinguished provider by MediFind in the treatment of Chronic Cough. Her top areas of expertise are Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and Bronchitis. Dr. Ice is currently accepting new patients.

Distinguished in Chronic Cough
Dr. Warren O. Whitlock
Family Medicine
Distinguished in Chronic Cough
Dr. Warren O. Whitlock
Family Medicine
130 Health Park Blvd, 
St Augustine, FL 
 (56.7 miles away)
904-826-3469
Languages Spoken:
English
See accepted insurances

Warren Whitlock is a primary care provider, practicing in Family Medicine in St Augustine, Florida. Dr. Whitlock is rated as an Advanced provider by MediFind in the treatment of Chronic Cough. His top areas of expertise are Chronic Cough, Graves Disease, Thyroid Storm, and Lung Metastases.

Advanced in Chronic Cough
Dr. John D. Bolla
Family Medicine
Advanced in Chronic Cough
Dr. John D. Bolla
Family Medicine
61 Memorial Medical Pkwy, Suite 3803, 
Palm Coast, FL 
 (31.0 miles away)
Languages Spoken:
English
See accepted insurances

John Bolla is a primary care provider, practicing in Family Medicine in Palm Coast, Florida. Dr. Bolla is rated as an Advanced provider by MediFind in the treatment of Chronic Cough. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Holocarboxylase Synthetase Deficiency, and ZAP70-Related Severe Combined Immunodeficiency.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rankin's expertise for a condition
ConditionClose
    View All 79 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile